Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3389934 in Sepsis Induced Coagulopathy
NCT06854640Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of BAY3389934 in sepsis-induced coagulopathy (SIC) (2 cohorts), sponsored by Bayer. Primary endpoints: Treatment-Emergent Adverse Events up to 97 hours and Severity of Treatment-Emergent Adverse Events up to 97 hours. Started Mar 2025; status: recruiting.
02
Drugs
BAY3389934
03
Conditions
sepsis-induced coagulopathy (SIC)
Beyond the preview
Go deeper on NCT06854640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854640.